Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients

被引:46
作者
Lang, Nina [1 ,2 ]
Dick, Julika [1 ,2 ]
Slynko, Alla [3 ]
Schulz, Carsten [1 ,2 ]
Dimitrakopoulou-Strauss, Antonia [4 ]
Sachpekidis, Christos [4 ]
Enk, Alexander H. [1 ,2 ]
Hassel, Jessica C. [1 ,2 ]
机构
[1] Univ Hosp Heidelberg, Dept Dermatol, Heidelberg, Germany
[2] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany
[3] Univ Appl Sci, Dept Math Nat & Econ Sci, Ulm, Germany
[4] German Canc Res Ctr Heidelberg, Clin Cooperat Unit Nucl Med, Heidelberg, Germany
关键词
F-18-FDG PET-CT; autoimmune colitis; checkpoint inhibition; immune-related adverse events; immunotherapy; ipilimumab; melanoma; treatment response; METASTATIC MELANOMA; ADVERSE EVENTS; F-18-FDG PET/CT; IPILIMUMAB; SURVIVAL; IMMUNOTHERAPY; MANAGEMENT;
D O I
10.2217/imt-2018-0146
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aim: Autoimmune colitis is a typical and possible severe side effect among patients treated with ipilimumab. Patients & methods: We prospectively included 100 patients with metastasized melanoma under ipilimumab treatment in a radiological study of F-18-fluorodeoxyglucose positron emission tomography-computed tomography (F-18-FDG PET-CT). PET evidence of pancolitis (PET-colitis') was correlated with clinical variables. Results: We observed a significant correlation between PET-colitis and clinically significant diarrhoea, although PET-colitis was more frequent (49 vs 29% of patients, respectively). Neither PET-colitis nor diarrhoea was significantly correlated with response to therapy. Other immune-related adverse events, however, such as hypophysitis and hepatitis were associated with response to therapy and overall survival. Conclusion: Increased F-18-FDG uptake in the colon correlated with clinical symptoms but did not predict clinical outcome to ipilimumab.
引用
收藏
页码:667 / 676
页数:10
相关论文
共 36 条
[1]   Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT [J].
Alabed, Yazan Z. ;
Aghayev, Ayaz ;
Sakellis, Christopher ;
Van den Abbeele, Annick D. .
CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) :e528-e529
[2]   ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].
ANDERSON, JR ;
CAIN, KC ;
GELBER, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719
[3]   Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab [J].
Anwar, Hoda ;
Sachpekidis, Christos ;
Winkler, Julia ;
Kopp-Schneider, Annette ;
Haberkorn, Uwe ;
Hassel, Jessica C. ;
Dimitrakopoulou-Strauss, Antonia .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) :376-383
[4]   Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis [J].
Bertrand, Anne ;
Kostine, Marie ;
Barnetche, Thomas ;
Truchetet, Marie-Elise ;
Schaeverbeke, Thierry .
BMC MEDICINE, 2015, 13
[5]  
Boursi B, 2018, MELANOMA RES, DOI 10.1097/cmr.0000000000000566
[6]   Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab [J].
Breki, Christina-Marina ;
Dimitrakopoulou-Strauss, Antonia ;
Hassel, Jessica ;
Theoharis, Theoharis ;
Sachpekidis, Christos ;
Pan, Leyun ;
Provata, Astero .
EJNMMI RESEARCH, 2016, 6
[7]   Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti-CTLA-4 Antibody Therapy [J].
Bronstein, Yulia ;
Ng, Chaan S. ;
Hwu, Patrick ;
Hwu, Wen-Jen .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2011, 197 (06) :W992-W1000
[8]   Biomarkers for Clinical Benefit of immune Checkpoint inhibitor Treatment-A Review From the Melanoma Perspective and Beyond [J].
Buder-Bakhaya, Kristina ;
Hassel, Jessica C. .
FRONTIERS IN IMMUNOLOGY, 2018, 9
[9]   Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme [J].
Di Giacomo, Anna Maria ;
Calabro, Luana ;
Danielli, Riccardo ;
Fonsatti, Ester ;
Bertocci, Erica ;
Pesce, Isabella ;
Fazio, Carolina ;
Cutaia, Ornella ;
Giannarelli, Diana ;
Miracco, Clelia ;
Biagioli, Maurizio ;
Altomonte, Maresa ;
Maio, Michele .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (06) :1021-1028
[10]   Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT [J].
Dirnitrakopoulou-Strauss, Antonia .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (05) :813-822